Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 14, 2019 at 10:32 AM.

  1. #1 cafead, Oct 14, 2019 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,013
    Likes Received:
    3
    via Exactly one year after kicking off a pivotal Phase III study for its lead drug — a companion for cancer patients receiving radiotherapy — Galera is looking to the Nasdaq for some new cash to complete the clinical work and fuel its commercial drive.

    article source
     
    Quote

Reply to Thread